Genetic polymorphisms in the development of anthracycline-induced cardiovascular toxicity in patients with follicular lymphoma

Aim. To identify genetic variants associated with the risk of developing anthracycline-induced cardiovascular toxicity during antitumor therapy in patients with follicular lymphoma.
Material and methods. The prospective study included 83 patients diagnosed with non-Hodgkin B-cell follicular lymphoma who received chemotherapy. Based on the results of follow-up standard and speckle-tracking echocardiography, the patients were divided into 2 groups: Group 1 — median age 59.0 (51.5; 69.0) years old, of which 44.1% were men (n=15), Group 2 — median age 55.0 (47.0; 66.5) years old, of which 55.1% were men (n=27)). Clinical, demographic, and laboratory assessments were performed, including high-throughput sequencing.
Results. Minor alleles of rs2072708, rs2072710, rs2075939 NCF4, rs1443638, rs2306422, rs72547284, rs11661275 CELF4, CYBA, and FHOD3; rs246232 ABCC1; rs3749442 ABCC5 are associated with an increased risk of anthracycline-induced cardiovascular toxicity. Minor alleles of rs2233260, rs3833910, rs7232329, rs8096379, rs200571909, rs625223, rs2566514 MYL2, MYOM1, NEB and NOS3; rs1128503, rs2032582, rs2214102, rs2235013, rs2235033, rs4728699 ABCB1; rs212088, rs35604 ABCC1; rs1056892 and rs2835286 CBR3; rs1549758 NOS3, rs3731750 TTN is associated with a reducedlikelihood of complications.
Conclusion. This study identified several novel genetic variants associated with the risk of cardiovascular toxicity, highlighting the potential for developing personalised approaches to anticancer therapy.

1. Mayborodin IV, Shumeikina AO, Mayborodina VI, Krasilnikov SE. Cardiotoxicity of Anticancer Drugs. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2024;69(9-10):91-107. (In Russ.)DOI:10.37489/0235-2990-2024-69-9-10-91-107

2. Vasyuk YA, Muslov SA, Vyzhigin DA, et al. Determining the risk of cardio- and vasotoxicity of antitumor therapy: who, when, and why? Kardiologiia. 2025;65(1):3-10. (In Russ.).

3. Poltavskaya MG, Novikova AI, Bezlyudsky AL. Cardiovascular diseases in the long term after surviving malignant neoplasm: a review. Consilium Medicum. 2025;27(8):438-45. (In Russ.).DOI:10.26442/20751753.2025.8.203064.

4. Buziashvili YI, Matskeplishvili ST, Asymbekova EU, et al. Molecular and genetic aspects ofcardiotoxicity of cancer chemotherapy. Kreativnaya kardiologiya. 2024;18(S):57-63. (In Russ). DOI:10.24022/1997-3187-2024-18S-S57-S63.

5. Vasyuk YA, Gendlin GE, Emelina EI, et al. Guidance letter for cardiologists of oncology institutions on the prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council on Cardiology, Russian Society of Cardiology. Cardiovascular therapy and prevention. 2023;22(7):3685. (In Russ).DOI:10.15829/1728-8800-2023-3685.

6. Visscher H, Ross CJ, Rassekh SR., et al.; Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422-8. DOI:10.1200/JCO.2010.34.3467.

7. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(13):1415-21. DOI:10.1200/JCO.2011.34.8987.

8. Khutornaya M, Khryachkova O, Sinitskaya A, et al. Role of the genes of the natriuretic peptide and antioxidant defense systems in creating the risk of myocardial infarction development (the preliminary results of a pilot study). Russian Medical Inquiry. 2023;7(1):5-12. (In Russ.)DOI:10.32364/2587-6821-2023-7-1-5-12

9. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004;18(6):664-75. DOI:10.1096/fj.03-0724rev.

10. McOwan TN, Craig LA, Tripdayonis A, et al. Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy. Cardiooncology. 2020;6:5. DOI:10.1186/s40959-020-00060-0.

11. Li X, Lin Y, Zhang R. Associations between endothelial nitric oxide synthase gene polymorphisms and the risk of coronary artery disease: A systematic review and meta-analysis of 132 case-control studies. Eur J Prev Cardiol. 2019;26(2):160-70. DOI:10.1177/2047487318780748.

12. Levinsson A, Olin AC, Björck L, et al. Nitric oxide synthase (NOS) single nucleotide polymorphisms are associated with coronary heart disease and hypertension in the INTERGENE study. Nitric Oxide. 2014;39:1-7. DOI:10.1016/j.niox.2014.03.164.

13. Kopeva KV, Grakova EV, Shilov SN, et al. Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors. Acta Cardiol. 2022;77(9):805-14. DOI:10.1080/00015385.2021.2003061.

14. Cejas RB, Petrykey K, Sapkota Y, Burridge PW. Anthracycline Toxicity: Light at the End of the Tunnel? Annu Rev Pharmacol Toxicol. 2024;64:115-34. DOI:10.1146/annurev-pharmtox-022823-035521.

15. Sag CM, Köhler AC, Anderson ME, et al. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 2011;51(5):749-59. DOI:10.1016/j.yjmcc.2011.07.016.

16. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140(1):31-41. DOI:10.1161/CIRCULATIONAHA.118.037934.

17. Yus’kiv YuA, Chernova AA, Nikulina SYu, et al. Molecular genetic characteristics of patients with hypertrophic cardiomyopathy: a review. Russian Journal of Cardiology. 2024;29(11S):5885. (In Russ.)DOI:10.15829/1560-4071-2024-5885

18. Azarova YЕ, Klyosova EY, Ivakin VE, et al. Polymorphisms of the NCF4 Gene Increase the Risk of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus. Bull Exp Biol Med. 2023;176(1):77-81. DOI:10.1007/s10517-023-05974-0.